| 1. |
- Abe, O, et al.
(författare)
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2005
-
Ingår i: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
-
Tidskriftsartikel (refereegranskat)abstract
- Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
|
|
| 2. |
- Beral, V, et al.
(författare)
-
Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease
- 2002
-
Ingår i: British Journal of Cancer. - : Springer Science and Business Media LLC. - 1532-1827 .- 0007-0920. ; 87, s. 1234-45
-
Tidskriftsartikel (refereegranskat)abstract
- Alcohol and tobacco consumption are closely correlated and published results on their association with breast cancer have not always allowed adequately for confounding between these exposures. Over 80% of the relevant information worldwide on alcohol and tobacco consumption and breast cancer were collated, checked and analysed centrally. Analyses included 58515 women with invasive breast cancer and 95067 controls from 53 studies. Relative risks of breast cancer were estimated, after stratifying by study, age, parity and, where appropriate, women's age when their first child was born and consumption of alcohol and tobacco. The average consumption of alcohol reported by controls from developed countries was 6.0 g per day, i.e. about half a unit/drink of alcohol per day, and was greater in ever-smokers than never-smokers, (8.4 g per day and 5.0 g per day, respectively). Compared with women who reported drinking no alcohol, the relative risk of breast cancer was 1.32 (1.19 - 1.45, P < 0.00001) for an intake of 35 - 44 g per day alcohol, and 1.46 (1.33 - 1.61, P < 0.00001) for greater than or equal to 45 g per day alcohol. The relative risk of breast cancer increased by 7.1% (95% CI 5.5-8.7%; P<0.00001) for each additional 10 g per day intake of alcohol, i.e. for each extra unit or drink of alcohol consumed on a daily basis. This increase was the same in ever-smokers and never-smokers (7.1 % per 10 g per day, P < 0.00001, in each group). By contrast, the relationship between smoking and breast cancer was substantially confounded by the effect of alcohol. When analyses were restricted to 22 255 women with breast cancer and 40 832 controls who reported drinking no alcohol, smoking was not associated with breast cancer (compared to never-smokers, relative risk for ever-smokers= 1.03, 95% CI 0.98 - 1.07, and for current smokers=0.99, 0.92 - 1.05). The results for alcohol and for tobacco did not vary substantially across studies, study designs, or according to 15 personal characteristics of the women; nor were the findings materially confounded by any of these factors. If the observed relationship for alcohol is causal, these results suggest that about 4% of the breast cancers in developed countries are attributable to alcohol. In developing countries, where alcohol consumption among controls averaged only 0.4 g per day, alcohol would have a negligible effect on the incidence of breast cancer. In conclusion, smoking has little or no independent effect on the risk of developing breast cancer; the effect of alcohol on breast cancer needs to be interpreted in the context of its beneficial effects, in moderation, on cardiovascular disease and its harmful effects on cirrhosis and cancers of the mouth, larynx, oesophagus and liver. (C) 2002 Cancer Research UK.
|
|
| 3. |
- Grahn, T., et al.
(författare)
-
Collectivity and configuration mixing in Pb186,188 and Po194
- 2006
-
Ingår i: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 97:6
-
Tidskriftsartikel (refereegranskat)abstract
- Lifetimes of prolate intruder states in Pb186 and oblate intruder states in Po194 have been determined by employing, for the first time, the recoil-decay tagging technique in recoil distance Doppler-shift lifetime measurements. In addition, lifetime measurements of prolate states in Pb188 up to the 8+ state were carried out using the recoil-gating method. The B(E2) values have been deduced from which deformation parameters |β2|=0.29(5) and |β2|=0.17(3) for the prolate and the oblate bands, respectively, have been extracted. The results also shed new light on the mixing between different shapes.
|
|
| 4. |
- Bashkanov, M., et al.
(författare)
-
Two-pion production in proton-proton collisions
- 2004
-
Ingår i: Hadron Spectroscopy, Tenth International Conference on Hadron Spectrscopy, Aschaffenburg, Germany 31 August - 6 September 2003. - 0735401977 ; , s. 241-244
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
|
|
| 6. |
- Nilsson, K. K., et al.
(författare)
-
Evolution in the properties of Lyman-α emitters from redshifts z ~ 3 to z ~ 2
- 2009
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 498:1, s. 13-23
-
Tidskriftsartikel (refereegranskat)abstract
- Context: Narrow-band surveys to detect Lyα emitters are powerful tools for identifying high, and very high, redshift galaxies. Although samples are increasing at redshifts z = 3 {-} 6, the nature of these galaxies is still poorly known. The number of galaxies detected at redshifts below z ˜ 3 are also small. Aims: We study the properties of z = 2.25 Lyα emitters and compare them with those of z > 3 Lyα emitters. Methods: We present narrow-band imaging made with the MPG/ESO 2.2m telescope and the WFI (Wide Field Imager) detector. Using this data, we have searched for emission-line objects. We find 170 candidate typical Lyα emitters and 17 candidates that we regard as high UV-transmission Lyα emitters. We have derived the magnitudes of these objects in 8 photometric bands from u* to K_s, and studied whether they have X-ray and/or radio counterparts. Results: We demonstrate that there has been significant evolution in the properties of Lyα emitters between redshift z ˜ 3 and z = 2.25. The spread in spectral energy distributions (SEDs) at the lower redshift is larger and we detect a significant AGN contribution in the sample. The distribution of the equivalent widths is narrower than at z ˜ 3, with only a few candidates with rest-frame equivalent width above the predicted limit of 240 Å. The star formation rates derived from the Lyα emission compared to those derived from the UV emission are lower by on average a factor of ˜ 1.8, indicative of a significant absorption by dust. Conclusions: Lyα emitters at redshift z = 2.25 may be more evolved than Lyα emitters at higher redshift. The red SEDs imply more massive, older and/or dustier galaxies at lower redshift than observed at higher redshifts. The decrease in equivalent widths and star formation rates indicate more quiescent galaxies, with in general less star formation than in higher redshift galaxies. At z = 2.25, AGN appear to be more abundant and also to contribute more to the Lyα emitting population. Full Table 2 is only available in electronic form at http://www.aanda.org
|
|
| 7. |
- Amnell, T, et al.
(författare)
-
Now, Next, and Future
- 2001
-
Ingår i: Modelling and Verification of Parallel Processes (MOVEP'2k), Nantes, France June 19 to 23, 2000. LNCS Tutorial 2067.. ; , s. 100-125
-
Konferensbidrag (refereegranskat)
|
|
| 8. |
- Astuto, L. M., et al.
(författare)
-
CDH23 mutation and phenotype heterogeneity : a profile of 107 diverse families with Usher syndrome and nonsyndromic deafness
- 2002
-
Ingår i: American Journal of Human Genetics. - : Elsevier BV. - 0002-9297 .- 1537-6605. ; 71:2, s. 262-275
-
Tidskriftsartikel (refereegranskat)abstract
- Usher syndrome type I is characterized by congenital hearing loss, retinitis pigmentosa (RP), and variable vestibular areflexia. Usher syndrome type ID, one of seven Usher syndrome type I genetic localizations, have been mapped to a chromosomal interval that overlaps with a nonsyndromic-deafness localization, DFNB12. Mutations in CDH23, a gene that encodes a putative cell-adhesion protein with multiple cadherin-like domains, are responsible for both Usher syndrome and DFNB12 nonsyndromic deafness. Specific CDH23 mutational defects have been identified that differentiate these two phenotypes. Only missense mutations of CDH23 have been observed in families with nonsyndromic deafness, whereas nonsense, frameshift, splice-site, and missense mutations have been identified in families with Usher syndrome. In the present study, a panel of 69 probands with Usher syndrome and 38 probands with recessive nonsyndromic deafness were screened for the presence of mutations in the entire coding region of CDH23, by heteroduplex, single-strand conformation polymorphism, and direct sequence analyses. A total of 36 different CDH23 mutations were detected in 45 families; 33 of these mutations were novel, including 18 missense, 3 nonsense, 5 splicing defects, 5 microdeletions, and 2 insertions. A total of seven mutations were common to more than one family. Numerous exonic and intronic polymorphisms also were detected. Results of ophthalmologic examinations of the patients with nonsyndromic deafness have found asymptomatic RP-like manifestations, indicating that missense mutations may have a subtle effect in the retina. Furthermore, patients with mutations in CDH23 display a wide range of hearing loss and RP phenotypes, differing in severity, age at onset, type, and the presence or absence of vestibular areflexia.
|
|
| 9. |
|
|
| 10. |
- Claudio, P., et al.
(författare)
-
Geochemical modelling application for a 1-d arsenic reactive transport study in alluvial aquifers, Matlab Upazila, Bangladesh
- 2009
-
Ingår i: Rendiconti Online della Società Geologica Italiana. - 2035-8008. ; 6, s. 364-365
-
Tidskriftsartikel (refereegranskat)abstract
- Mechanistic modelling was used to investigate the hydrochemical evolution along a vertical column, should cross-contamination occur. 1-D reactive transport was carried out to assess sorption effects on aqueous/solid arsenic distribution in Matlab Upazila, Bangladesh. Thermodynamic relationships between aqueous ions and aquifer materials have been investigated: comparison between redox couples shows electrochemical disequilibrium; sorption mainly occurs on weak and strong Hydrous Ferric-Oxides, described by the Surface Complexation Mode. The basis for reactive transport calculations is given by a static model, that evaluates the competing ions net effect: they reduce by ca. 50% arsenic bounding. Desorption process alone can give unacceptable As (aq) concentrations, starting from only a few mg/kg As (sorb). Redox zonation was the starting point for the model conception, which allowed calculating the contamination evolution in an oxidising As-low aquifer. Groundwater analysis is worked out for a 20 cells column of aquifer material, whose top represents the upper reducing aquifer, the bottom the oxidising aquifer; contamination takes place through an As-rich solution percolating into the column. Results are a function of the flow velocity, that needs to be carefully defined before further modelling.
|
|
